Skip to main content
Top
Published in: Clinical Rheumatology 4/2006

01-07-2006 | Brief Report

Focal transient lesions of the corpus callosum in systemic lupus erythematosus

Authors: Simone Appenzeller, Andreia Faria, Roberto Marini, Lilian Tereza Lavras Costallat, Fernando Cendes

Published in: Clinical Rheumatology | Issue 4/2006

Login to get access

Abstract

Focal lesions limited to the splenium of the corpus callosum are rare and little is known about their etiology. We describe three patients with systemic lupus erythematosus (SLE) that presented transient lesions of the corpus callosum. We reviewed three patients with SLE whose magnetic resonance imaging (MRI) results revealed focal lesions in the splenum of corpus callosum. The medical records, including clinical, serological, and treatment features, were reviewed to determine the etiology of these lesions. Of 115 patients who had MRI for research purposes, three patients with focal nonhemorrhagic lesions of the corpus callosum were identified. All patients had active SLE at the time of MRI. One patient had other findings on MRI, including cerebral venous thrombosis. On follow-up MRI, patients had an inactive disease and the corpus callosum lesions disappeared. A transient lesion in the splenium of corpus callosum seems to be a nonspecific endpoint of different disease processes leading to vasogenic edema. The complete and rapid reversibility in all cases with disease control is emphasized and any invasive diagnostic or therapeutic approach is discouraged.
Literature
1.
go back to reference Kovacs J, Urowitz M, Gladman D (1993) Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 19:795–819PubMed Kovacs J, Urowitz M, Gladman D (1993) Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 19:795–819PubMed
2.
go back to reference Hanly JG, Walsh NM, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741PubMed Hanly JG, Walsh NM, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741PubMed
3.
go back to reference Leiguarda R, Starkstein S, Berthier M (1989) Anterior callosal hemorrhage: a partial interhemispheric disconnection syndrome. Brain 112:1019–1037PubMedCrossRef Leiguarda R, Starkstein S, Berthier M (1989) Anterior callosal hemorrhage: a partial interhemispheric disconnection syndrome. Brain 112:1019–1037PubMedCrossRef
4.
go back to reference Kuker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M, Weller M, Herrlinger U (2005) Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72:169–177CrossRefPubMed Kuker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M, Weller M, Herrlinger U (2005) Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72:169–177CrossRefPubMed
5.
go back to reference Rabbani O, Bowen LE, Watson RT et al (2004) Alien limb syndrome and Moya-Moya disease. Mov Disord 19:1317–1320CrossRefPubMed Rabbani O, Bowen LE, Watson RT et al (2004) Alien limb syndrome and Moya-Moya disease. Mov Disord 19:1317–1320CrossRefPubMed
6.
go back to reference Moroni C, Belin C, Haguenau M et al (2004) Clinical callosum syndrome in a case of multiple sclerosis. Eur J Neurol 11:209–212CrossRefPubMed Moroni C, Belin C, Haguenau M et al (2004) Clinical callosum syndrome in a case of multiple sclerosis. Eur J Neurol 11:209–212CrossRefPubMed
7.
go back to reference Takayama H, Kobayashi K, Sugishita M, Mihara B (2000) Diffusion-weighted imaging demonstrates transient cytotoxicedema involving the corpus callosum in a patient with diffuse brain injury. Clin Neurol Neurosurg 102:135–139CrossRefPubMed Takayama H, Kobayashi K, Sugishita M, Mihara B (2000) Diffusion-weighted imaging demonstrates transient cytotoxicedema involving the corpus callosum in a patient with diffuse brain injury. Clin Neurol Neurosurg 102:135–139CrossRefPubMed
8.
go back to reference Kim SS, Chang KH, Kim ST, Suh DC, Cheon JE, Jeong SW, Han MH, Lee SK (1999) Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? AJNR Am J Neuroradiol 20:125–129PubMed Kim SS, Chang KH, Kim ST, Suh DC, Cheon JE, Jeong SW, Han MH, Lee SK (1999) Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? AJNR Am J Neuroradiol 20:125–129PubMed
9.
go back to reference Polster T, Hoppe M, Ebner A (2001) Transient lesion in the splenium of the corpus callosum: three further cases in epileptic patients and a pathophysiological hypothesis. J Neurol Neurosurg Psychiatry 70:459–463CrossRefPubMed Polster T, Hoppe M, Ebner A (2001) Transient lesion in the splenium of the corpus callosum: three further cases in epileptic patients and a pathophysiological hypothesis. J Neurol Neurosurg Psychiatry 70:459–463CrossRefPubMed
10.
go back to reference Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
11.
go back to reference Liang MH, Corzillius M, Bae SC et al (1999) The American College nomenclature and case definitions for neuropsychiatric lupus syndrome. Arthritis Rheum 42:599–608CrossRefPubMed Liang MH, Corzillius M, Bae SC et al (1999) The American College nomenclature and case definitions for neuropsychiatric lupus syndrome. Arthritis Rheum 42:599–608CrossRefPubMed
12.
go back to reference Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F (2005) Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 52:2783–2789CrossRefPubMed Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F (2005) Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 52:2783–2789CrossRefPubMed
13.
go back to reference Hiroshi Ogura, Makoto Takaoka, Masashi Kishi, Masahide Kimoto, Takeshi Shimazu, Toshiharu Yoshioka, Hisashi Sugimoto (1998) Reversible MR findings of hemolytic uremic syndrome with mild encephalopathy. Am J Neuroradiol 19:1144–1145PubMed Hiroshi Ogura, Makoto Takaoka, Masashi Kishi, Masahide Kimoto, Takeshi Shimazu, Toshiharu Yoshioka, Hisashi Sugimoto (1998) Reversible MR findings of hemolytic uremic syndrome with mild encephalopathy. Am J Neuroradiol 19:1144–1145PubMed
14.
go back to reference Schulte T, Sullivan EV, Muller-Oehring EM, Adalsteinsson E, Pfefferbaum A (2005) Corpus callosal microstructural integrity influences interhemispheric processing: a diffusion tensor imaging study. Cereb Cortex 15:1384–1392CrossRefPubMed Schulte T, Sullivan EV, Muller-Oehring EM, Adalsteinsson E, Pfefferbaum A (2005) Corpus callosal microstructural integrity influences interhemispheric processing: a diffusion tensor imaging study. Cereb Cortex 15:1384–1392CrossRefPubMed
15.
go back to reference Kakou M, Velut S, Destrieux C (1998) Vascularisation artérielle et veineuse du corps calleux. Neurochirurgie 4:31–37 Kakou M, Velut S, Destrieux C (1998) Vascularisation artérielle et veineuse du corps calleux. Neurochirurgie 4:31–37
16.
go back to reference Aboitiz F, Scheibel AB, Fisher RS et al (1992) Fiber composition of the human corpus callosum. Brain Res 558:143–153CrossRef Aboitiz F, Scheibel AB, Fisher RS et al (1992) Fiber composition of the human corpus callosum. Brain Res 558:143–153CrossRef
Metadata
Title
Focal transient lesions of the corpus callosum in systemic lupus erythematosus
Authors
Simone Appenzeller
Andreia Faria
Roberto Marini
Lilian Tereza Lavras Costallat
Fernando Cendes
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0174-1

Other articles of this Issue 4/2006

Clinical Rheumatology 4/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine